Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Whitepaper Compares Targeted Resequencing Strategies

Published: Wednesday, July 17, 2013
Last Updated: Wednesday, July 17, 2013
Bookmark and Share
OGT provides insight into choice of NGS methods.

Oxford Gene Technology (OGT) has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing - Choosing the right NGS method.’

The paper aims to assist researchers when planning NGS strategies by providing a detailed review of the major resequencing methods.

Comparing and contrasting method suitability, the paper also examines the significant impact of data analysis, as well as time and cost considerations.

OGT has written the whitepaper in response to a growing demand from within its customer base and the NGS community for a balanced and comprehensive guide to targeted resequencing strategies.

Considered from both clinical research and discovery viewpoints, the paper discusses whole exome and targeted panel sequencing strategies, without bias.

This includes highlighting the limitations of each approach, and offering advice on when whole genome sequencing is appropriate, providing researchers with insight to identify the most suitable method for the task at hand.

Considerations are also presented on choice of capture technologies, bait design and the use of service providers for method optimization and accessibility to meaningful results.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Announces Commercial and Financial Highlights for FY 2015
New products launched across all core brands; Cytocell® FISH, SureSeq™ NGS and CytoSure™ arrays for cancer and rare disease.
Saturday, December 12, 2015
OGT Licenses SNP Probe Technology to BMGL
Proprietary technology allows superior LOH detection in challenging samples.
Friday, November 13, 2015
OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Friday, July 17, 2015
OGT Signs License with Wellcome Trust Sanger Institute
OGT will use novel data on developmental disorders to advance microarray and NGS products for accurate and cost effective identification of rare diseases.
Saturday, April 04, 2015
Oxford Gene Technology Awarded £1.2m Genomics England Contract
Next Generation Sequencing analysis software will support 100,000 Genomes Project by providing intuitive reports for clinical interpretation.
Monday, March 16, 2015
OGT Announces Operational and Financial Highlights for FY 2014
OGT’s molecular genetics business delivers 54% growth in commercial revenues to £11.9m.
Tuesday, December 09, 2014
Pieces of the Puzzle - A Multi-method Approach to Tumour Profiling
OGT workshop provides insight on using complementary genomic technologies.
Friday, November 07, 2014
An Integrated Approach to Clinical Genetics Research
OGT’s new whitepaper explores the next stage of molecular testing.
Wednesday, April 09, 2014
OGT Announces Acquisition of Cytocell Ltd
Company expands leadership in genomic medicine.
Thursday, March 06, 2014
Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
OGT Initiates Strategic Expansion Plans in North America
Opening of New York office and appointment of US sales team.
Tuesday, November 20, 2012
Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!